For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?

Annals of Oncology

Volumn 9, Issue 2, 1998, Pages 191-194

  Bos, G M J ^a   Van Putten, W L J ^a   Van Der Holt, B ^a   Van Den Bent, M ^a   Verdonck, L F ^b   Hagenbeek, A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Central nervous system disease; Non Hodgkin's lymphoma; Prophylactic treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; HIGH RISK PATIENT; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0031938758     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008260120532     Document Type: Article

References (15)

1. Ersboll J, Schultz HB, Thompson BLR, et al. Meningeal involvement in non-Hodgkin's lymphoma: Symptoms, incidence, risk factors and treatment. Scand J Haematol 1985; 35: 487-96.
2. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: The risk factors. Hematol Oncol 1990; 8: 141-5.
3. Johnson GJ, Oken MM, Anderson JR, et al. Central nervous system relapse in unfafourable-histology non-Hodgkin's lymphoma: Is prophylaxis indicated? Lancet 1984; 22: 685-7.
4. Levitt LJ, Dawson DM, Rosenthal DS et al. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980; 45: 545-52.
5. Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggresive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14: 478-82.
6. Mackintosh FR, Colby TV, Podolsky WJ et al. Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases. Cancer 1982; 49: 586-95.
7. Litam JP, Cabanillas F, Smith TL et al. Central nervous system relapse in malignant lymphomas: Risk factors and implications for prophylaxis. Blood 1979; 54: 1249-57.
8. Bollen ELEM, Brouwer RE, Hamers S et al. Central nervous system (CNS) relapse in non-Hodgkin's lymphoma: a single-center study of 553 patients. Arch Neurol 1997; 54: 854-9.
9. Sheehan T, Cuthbert RJG, Parker AC. Central nervous system involvement in haematological malignancies. Clin Lab Haemat 1989; 11: 331-8.
10. Recht L, Straus DJ, Cirrincione C et al. Central nervous system metastasis form non-Hodgkin's lymphoma: Treatment and prophylaxis. Am J Med 1988; 84: 425-35.
11. Young RC, Howser DM, Andersen T et al. Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med 1979; 66: 435-43.
12. Perez-Soler R, Smith TL, Cabanillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive hitologic type. Cancer 1986; 57: 971-7.
13. Liang RHS, Woo EKW, Yu Y-L et al. Central nervous system involvement in non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1989; 25: 703-10.
14. Shipp MA, Harrington DP. For the international Non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
15. Verdonck LF, Van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-51.